Login Register Cart 0
Generic placeholder image

Current Cancer Therapy Reviews

Editor-in-Chief

ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Role of the Pharmacist in the Management of Polypharmacy and Drug Interactions in the Elderly Patient with Chemotherapy

Author(s): Silvania Maria Saldanha de Souza, José Cleberson Santos Soares and Iago Dillion Lima Cavalcanti*

Volume 20, Issue 1, 2024

Published on: 22 May, 2023

Page: [2 - 11] Pages: 10

DOI: 10.2174/1573394719666230403110650

Price: $65

Abstract

Introduction: This study aimed to review the role of the pharmacist in cases of polypharmacy in the care of elderly patients with cancer.

Methods: An narrative literature review was carried out using the descriptors "Polypharmacy", "Pharmacological interactions", "Geriatrics" and "Antineoplastic agents", in the ScienceDirect, MEDLINE, and CAPLUS databases.

Results: One hundred and ten articles were identified, of which 82 were included in this review. The articles showed the importance of evaluating drug interactions in the treatment of cancer in oncogeriatric patients due to the high amount of drugs that these patients use, which can exceed 6 drugs per day, and that these interactions can compromise the treatment of the patient, as well as induce serious toxic effects, causing the patient to be hospitalized or even die.

Conclusion: The inclusion of the pharmacist in the care of oncogeriatric patients reduces the risk of interaction through pharmacotherapeutic monitoring.

« Previous Next »
Graphical Abstract

[1]
Duarte MB, Rego MAV. Comorbidity between depression and clinical diseases in a geriatric outpatient clinic. Cad Saude Publica 2007; 23(3): 691-700.
[http://dx.doi.org/10.1590/S0102-311X2007000300027] [PMID: 17334582]
[2]
Melgaço TB, Carrera J de S, do Nascimento DEB. Maia C do SF. Polypharmacy and occurrences of possible drug interactions. Rev Med 2011; 25(1)
[3]
Leal MCC, Marques APO, Marino JG, Austregésilo SC. Profile of nursing homes in the city of Recife, PE, Brazil. Rev Bras Geriatr Gerontol 2006; 9(3): 39-48.
[http://dx.doi.org/10.1590/1809-9823.2006.09034]
[4]
Vespa J, Medina L, Armstrong DM. Demographic turning points for the United States: Population projections for 2020 to 2060 US Census Bur 2020; 1-15.
[5]
Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000; 35(3): 181-200.
[http://dx.doi.org/10.1016/S1040-8428(00)00090-1] [PMID: 10960800]
[6]
Satariano WA, Silliman RA. Comorbidity: Implications for research and practice in geriatric oncology. Crit Rev Oncol Hematol 2003; 48(2): 239-48.
[http://dx.doi.org/10.1016/j.critrevonc.2003.08.002] [PMID: 14607386]
[7]
Stefanacci RG, Khan T. Can managed care manage polypharmacy? Clin Geriatr Med 2017; 33(2): 241-55.
[http://dx.doi.org/10.1016/j.cger.2017.01.005] [PMID: 28364994]
[8]
Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: Evaluating risks and deprescribing. Am Fam Physician 2019; 100(1): 32-8.
[PMID: 31259501]
[9]
Cavalcanti IDL. Plypharmacy in cancer therapy. Chemotherapy protocols and infusion sequence: Schedule considerations in cancer treatment. Cham: Springer 2022.
[http://dx.doi.org/10.1007/978-3-031-10839-6_1]
[10]
Faria C de O, Reis CM, Santos AG, Reis AMM. Drug interactions in elderly cancer patients treated at a hematology-oncology outpatient clinic. Rev Bras Cancerol 2018; 64(1): 61-8.
[http://dx.doi.org/10.32635/2176-9745.RBC.2018v64n1.119]
[11]
Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev 2019; 4(1): 5.
[http://dx.doi.org/10.1186/s41073-019-0064-8] [PMID: 30962953]
[12]
Borges GM. Health transition in Brazil: Regional variations and divergence/convergence in mortality. Cad Saude Publica 2017; 33(8): e00080316.
[http://dx.doi.org/10.1590/0102-311x00080316] [PMID: 28832781]
[13]
Francisco PMSB, Friestino JKO, Ferraz R de O, Bacurau AG de M, Stopa SR, Filho D de CM. Prevalence of diagnosis and types of câncer in the elderly: Data from national health survey 2013. Rev Bras Geriatr Gerontol 2020; 23(2)
[http://dx.doi.org/10.1590/1981-22562020023.200023]
[14]
(WHO). Chronic diseases. Available from:. https://www.who.int/health-topics/noncommunicable-diseases#tab=tab_1 (Accessed November 13, 2020).
[15]
Silva NM, dos Santos MA, de Oliveira RAA, et al. Elderly undergoing chemotherapy: Relationship between stress level, depressive symptoms and hope. Psychol: Theory Res 2019; 35: e35441.
[16]
Beinse G, Reitter D, Segaux L, et al. Potential drug-drug interactions and risk of unplanned hospitalization in older patients with cancer: A survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort. J Geriatr Oncol 2020; 11(4): 586-92.
[http://dx.doi.org/10.1016/j.jgo.2019.07.023] [PMID: 31445850]
[17]
Marques GFM, Rezende DMRP, Silva IP, et al. Polypharmacy and potentially inappropriate medications for elder people in gerontological nursing. Rev Bras Enferm 2018; 71(5): 2440-6.
[http://dx.doi.org/10.1590/0034-7167-2017-0211] [PMID: 30304174]
[18]
Pomatto LCD, Davies KJA. The role of declining adaptive homeostasis in ageing. J Physiol 2017; 595(24): 7275-309.
[http://dx.doi.org/10.1113/JP275072] [PMID: 29028112]
[19]
Atamna H, Tenore A, Lui F, Dhahbi JM. Organ reserve, excess metabolic capacity, and aging. Biogerontology 2018; 19(2): 171-84.
[http://dx.doi.org/10.1007/s10522-018-9746-8] [PMID: 29335816]
[20]
Singh JC, Lichtman SM. Effect of age on drug metabolism in women with breast cancer. Expert Opin Drug Metab Toxicol 2015; 11(5): 757-66.
[http://dx.doi.org/10.1517/17425255.2015.1037277] [PMID: 25940027]
[21]
Fuentes E, Fuentes M, Alarcón M, Palomo I. Immune system dysfunction in the elderly An Acad Bras Cienc 2017; 89(1)
[22]
Rougé Bugat ME, Bourgouin M, Gérard S, et al. Drug prescription including interactions with anticancer treatments in the elderly: A global approach. J Nutr Health Aging 2017; 21(8): 849-54.
[http://dx.doi.org/10.1007/s12603-017-0946-8] [PMID: 28972235]
[23]
Teixeira AKS, Vasconcelos JLA. Histopathological profile of patients diagnosed with malignant tumors assisted in a hospital of reference of Agreste Pernambucano. J Bras Patol Med Lab 2019; 55(1): 87-97.
[http://dx.doi.org/10.5935/1676-2444.20190002]
[24]
Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol 2018; 36(22): 2326-47.
[http://dx.doi.org/10.1200/JCO.2018.78.8687] [PMID: 29782209]
[25]
Taberna M, Gil Moncayo F, Jané-Salas E, et al. The multidisciplinar team (MDT) approach and quality of care. Front Oncol 2020; 10: 85.
[http://dx.doi.org/10.3389/fonc.2020.00085] [PMID: 32266126]
[26]
Schmidt H, Boese S, Lampe K, et al. Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatric oncology patients (PIVOG). J Geriatr Oncol 2017; 8(4): 262-70.
[http://dx.doi.org/10.1016/j.jgo.2017.04.002] [PMID: 28533106]
[27]
Cavalcanti I. Chemotherapy Protocols and Infusion Sequence: Schedule Considerations in Cancer Treatment. 2022.
[http://dx.doi.org/10.1007/978-3-031-10839-6]
[28]
Jingwen B, Yaochen L, Guojun Z. Cell cycle regulation and anticancer drug discovery. Cancer Biol Med 2017; 14(4): 348-62.
[http://dx.doi.org/10.20892/j.issn.2095-3941.2017.0033] [PMID: 29372101]
[29]
Cavalcanti I, Soares J. Conventional cancer treatment. Advances in Cancer Treatment 2021.
[http://dx.doi.org/10.1007/978-3-030-68334-4_4]
[30]
Calixto-Lima L, Martins de Andrade E, Gomes AP, Geller M, Siqueira-Batista R. Dietetic management in gastrointestinal complications from antimalignant chemotherapy. Nutr Hosp 2012; 27(1): 65-75.
[http://dx.doi.org/10.1590/S0212-16112012000100008] [PMID: 22566305]
[31]
Saponara M, Gatto L, Di Nunno V, et al. Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. Anticancer Drugs 2016; 27(4): 353-63.
[http://dx.doi.org/10.1097/CAD.0000000000000331] [PMID: 26720290]
[32]
Stout NL, Sabo Wagner S. Antineoplastic therapy side effects and polypharmacy in older adults with cancer. Top Geriatr Rehabil 2019; 35(1): 15-30.
[http://dx.doi.org/10.1097/TGR.0000000000000212] [PMID: 31011239]
[33]
Magalhaes LG, Ferreira LLG, Andricopulo AD. Recent advances and perspectives in cancer drug design. An Acad Bras Cienc 2018; 90(1) (Suppl. 2): 1233-50.
[34]
Delou JMA, Souza ASO, Souza LCM, Borges HL. Highlights in resistance mechanism pathways for combination therapy. Cells 2019; 8(9): 1013.
[http://dx.doi.org/10.3390/cells8091013] [PMID: 31480389]
[35]
Rougé Bugat ME, Bréchemier D, Balardy L. Polypharmacy and potentially inappropriate medication use among senior adults with cancer: what is the best approach? J Clin Oncol 2015; 33(34): 4123-4.
[http://dx.doi.org/10.1200/JCO.2015.62.8149] [PMID: 26351346]
[36]
Williams GR, Mackenzie A, Magnuson A, et al. Comorbidity in older adults with cancer. J Geriatr Oncol 2016; 7(4): 249-57.
[http://dx.doi.org/10.1016/j.jgo.2015.12.002] [PMID: 26725537]
[37]
Mokhtari RB, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget 2017; 8(23): 38022-43.
[http://dx.doi.org/10.18632/oncotarget.16723] [PMID: 28410237]
[38]
Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci 2020; 21(9): 3233.
[http://dx.doi.org/10.3390/ijms21093233] [PMID: 32370233]
[39]
Lees J, Chan A. Polypharmacy in elderly patients with cancer: Clinical implications and management. Lancet Oncol 2011; 12(13): 1249-57.
[http://dx.doi.org/10.1016/S1470-2045(11)70040-7] [PMID: 21741307]
[40]
Aszalos A. P-Glycoprotein-based drug-drug interactions: Preclinical methods and relevance to clinical observations. Arch Pharm Res 2004; 27(2): 127-35.
[http://dx.doi.org/10.1007/BF02980095] [PMID: 15022711]
[41]
Lonsdale DO, Baker EH. Understanding and managing medication in elderly people. Best Pract Res Clin Obstet Gynaecol 2013; 27(5): 767-88.
[http://dx.doi.org/10.1016/j.bpobgyn.2013.06.002] [PMID: 23850054]
[42]
Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1). Drug Discov Today 2007; 12(19-20): 838-43.
[http://dx.doi.org/10.1016/j.drudis.2007.07.021] [PMID: 17933685]
[43]
Del Re M, Fogli S, Derosa L, et al. The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treat Rev 2017; 55: 71-82.
[http://dx.doi.org/10.1016/j.ctrv.2017.03.001] [PMID: 28340451]
[44]
Carcelero E, Anglada H, Tuset M, Creus N. Interactions between oral antineoplastic agents and concomitant medication: A systematic review. Expert Opin Drug Saf 2013; 12(3): 403-20.
[http://dx.doi.org/10.1517/14740338.2013.784268] [PMID: 23586848]
[45]
MonteiroCR de ASchoueri JHM, Cardial DT, et al. Evaluation of the systemic and therapeutic repercussions caused by drug interactions in oncology patients. Rev Assoc Med Bras 2019; 65(5): 611-7.
[46]
Thomas-Schoemann A, Blanchet B, Bardin C, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol 2014; 89(1): 179-96.
[http://dx.doi.org/10.1016/j.critrevonc.2013.08.007] [PMID: 24041628]
[47]
Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: Current insights. Integr Pharm Res Pract 2017; 6: 37-46.
[http://dx.doi.org/10.2147/IPRP.S108047] [PMID: 29354549]
[48]
Clairet AL, Boiteux-Jurain M, Curtit E, et al. Interaction between phytotherapy and oral anticancer agents: Prospective study and literature review. Med Oncol 2019; 36(5): 45.
[http://dx.doi.org/10.1007/s12032-019-1267-z] [PMID: 30993543]
[49]
Domínguez-Alonso JA, Conde-Estévez D, Bosch D, Pi-Figueras M, Tusquets I. Breast cancer, placing drug interactions in the spotlight: Is polypharmacy the cause of everything? Clin Transl Oncol 2021; 23(1): 65-73.
[http://dx.doi.org/10.1007/s12094-020-02386-8] [PMID: 32449126]
[50]
Balducci L, Goetz-Parten D, Steinman MA. Polypharmacy and the management of the older cancer patient. Ann Oncol 2013; 24 (Suppl. 7): vii36-40.
[http://dx.doi.org/10.1093/annonc/mdt266] [PMID: 24001761]
[51]
de Boer AZ, Derks MGM, de Glas NA, et al. Metastatic breast cancer in older patients: A longitudinal assessment of geriatric outcomes. J Geriatr Oncol 2020; 11(6): 969-75.
[http://dx.doi.org/10.1016/j.jgo.2020.04.002] [PMID: 32381437]
[52]
Pamoukdjian F, Aparicio T, Zelek L, et al. Impaired mobility, depressed mood, cognitive impairment and polypharmacy are independently associated with disability in older cancer outpatients: The prospective Physical Frailty in Elderly Cancer patients (PF-EC) cohort study. J Geriatr Oncol 2017; 8(3): 190-5.
[http://dx.doi.org/10.1016/j.jgo.2017.02.003] [PMID: 28236586]
[53]
Götze H, Köhler N, Taubenheim S, Lordick F, Mehnert A. Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health. J Geriatr Oncol 2019; 10(1): 55-9.
[http://dx.doi.org/10.1016/j.jgo.2018.05.011] [PMID: 29880406]
[54]
Festen S, van der Wal-Huisman H, van der Leest AHD, et al. The effect of treatment modifications by an onco-geriatric MDT on one-year mortality, days spent at home and postoperative complications. J Geriatr Oncol 2021; 12(5): 779-85.
[http://dx.doi.org/10.1016/j.jgo.2020.12.003] [PMID: 33342722]
[55]
Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials: Methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med 2012; 28(2): 237-53.
[http://dx.doi.org/10.1016/j.cger.2012.01.006] [PMID: 22500541]
[56]
Qerem WA, Bashir Jarrar Y, Sheikh IA, ElMaadani A. The prevalence of drug-drug interactions and polypharmacy among elderly patients in Jordan. Biomed Res 2018; 29(12)
[http://dx.doi.org/10.4066/biomedicalresearch.29-18-618]
[57]
Wang J, Shen JY, Yu F, et al. Medications associated with geriatric syndromes (MAGS) and hospitalization risk in home health care patients. J Am Med Dir Assoc 2022; 10: 1627-33.
[http://dx.doi.org/10.1016/j.jamda.2022.03.012]
[58]
Kose E, Wakabayashi H, Yasuno N. Polypharmacy and malnutrition management of elderly perioperative patients with cancer: a systematic review. Nutrients 2021; 13(6): 1961.
[http://dx.doi.org/10.3390/nu13061961] [PMID: 34200493]
[59]
Lu-Yao G, Nightingale G, Nikita N, et al. Relationship between polypharmacy and inpatient hospitalization among older adults with cancer treated with intravenous chemotherapy. J Geriatr Oncol 2020; 11(4): 579-85.
[http://dx.doi.org/10.1016/j.jgo.2020.03.001] [PMID: 32199776]
[60]
Nightingale G, Pizzi LT, Barlow A, et al. The prevalence of major drug-drug interactions in older adults with cancer and the role of clinical decision support software. J Geriatr Oncol 2018; 9(5): 526-33.
[http://dx.doi.org/10.1016/j.jgo.2018.02.001] [PMID: 29510896]
[61]
Outlaw D, Dai C, Al-Obaidi M, et al. The association of polypharmacy with functional status impairments, frailty, and health-related quality of life in older adults with gastrointestinal malignancy - Results from the Cancer and Aging Resilience Evaluation (CARE) registry. J Geriatr Oncol 2022; 13(5): 624-8.
[http://dx.doi.org/10.1016/j.jgo.2021.12.010] [PMID: 34998720]
[62]
Ramsdale E, Lemelman T, Loh KP, et al. Geriatric assessment-driven polypharmacy discussions between oncologists, older patients, and their caregivers. J Geriatr Oncol 2018; 9(5): 534-9.
[http://dx.doi.org/10.1016/j.jgo.2018.02.007] [PMID: 29530495]
[63]
Leger DY, Moreau S, Signol N, et al. Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: Observational single-center study of 122 patients. J Geriatr Oncol 2018; 9(1): 60-7.
[http://dx.doi.org/10.1016/j.jgo.2017.07.015] [PMID: 28851511]
[64]
Munir A, Huws A, Khan S, Sharaiha Y, Holt S, Khawaja S. Geriatric assessment tool application in treatment recommendations for older women with breast cancer. Breast 2022; 63: 101-7.
[http://dx.doi.org/10.1016/j.breast.2022.03.012] [PMID: 35366503]
[65]
Hakozaki T, Matsuo T, Shimizu A, Ishihara Y, Hosomi Y. Polypharmacy among older advanced lung cancer patients taking EGFR tyrosine kinase inhibitors. J Geriatr Oncol 2021; 12(1): 64-71.
[http://dx.doi.org/10.1016/j.jgo.2020.09.011] [PMID: 32952094]
[66]
Sugidono M, Lo M, Young R, et al. Impact of polypharmacy prior to allogeneic hematopoietic stem cell transplantation in older adults. Transplant Cell Ther 2021; 27(4): 344.e1-5.
[http://dx.doi.org/10.1016/j.jtct.2021.01.001] [PMID: 33836888]
[67]
Prithviraj GK, Koroukian S, Margevicius S, Berger NA, Bagai R, Owusu C. Patient characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. J Geriatr Oncol 2012; 3(3): 228-37.
[http://dx.doi.org/10.1016/j.jgo.2012.02.005] [PMID: 22712030]
[68]
Choukroun C, Leguelinel-Blache G, Roux-Marson C, et al. Impact of a pharmacist and geriatrician medication review on drug-related problems in older outpatients with cancer. J Geriatr Oncol 2021; 12(1): 57-63.
[http://dx.doi.org/10.1016/j.jgo.2020.07.010] [PMID: 32800700]
[69]
Lattanzio F, Laino I, Pedone C, et al. Geriatric conditions and adverse drug reactions in elderly hospitalized patients. J Am Med Dir Assoc 2012; 13(2): 96-9.
[http://dx.doi.org/10.1016/j.jamda.2011.04.006] [PMID: 21621472]
[70]
Jeon MS, Jeong YM, Yee J, et al. Association of pre-operative medication use with unplanned 30-day hospital readmission after surgery in oncology patients receiving comprehensive geriatric assessment. Am J Surg 2020; 219(6): 963-8.
[http://dx.doi.org/10.1016/j.amjsurg.2019.06.020] [PMID: 31255260]
[71]
Sirois C, Turner JP, Hébert J. Health professionals’ perspectives regarding polypharmacy in older patients with cancer: A mixed-design exploratory study. J Geriatr Oncol 2021; 12(6): 881-7.
[http://dx.doi.org/10.1016/j.jgo.2021.02.027] [PMID: 33750672]
[72]
Jørgensen TL, Herrstedt J. The influence of polypharmacy, potentially inappropriate medications, and drug interactions on treatment completion and prognosis in older patients with ovarian cancer. J Geriatr Oncol 2020; 11(4): 593-602.
[http://dx.doi.org/10.1016/j.jgo.2019.12.005] [PMID: 31883969]
[73]
Ramasubbu SK, Mahato SK, Agnihotri A, Pasricha RK, Nath UK, Das B. Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: A prospective study in a tertiary care teaching hospital. Cancer Treat Res Commun 2021; 26: 100277.
[http://dx.doi.org/10.1016/j.ctarc.2020.100277] [PMID: 33348276]
[74]
Iurlo A, Ubertis A, Artuso S, et al. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients. Eur J Intern Med 2014; 25(1): 63-6.
[http://dx.doi.org/10.1016/j.ejim.2013.11.002] [PMID: 24309387]
[75]
Woopen H, Richter R, Ismaeel F, et al. The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer. Gynecol Oncol 2016; 140(3): 554-8.
[http://dx.doi.org/10.1016/j.ygyno.2016.01.012] [PMID: 26790772]
[76]
Popa MA, Wallace KJ, Brunello A, Extermann M, Balducci L. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol 2014; 5(3): 307-14.
[http://dx.doi.org/10.1016/j.jgo.2014.04.002] [PMID: 24821377]
[77]
Narjoux G, Clarenne J, Azzouz B, Zeller P, Slimano F, Bouché O. Nightmares and hallucinations with aprepitant and opium powder: A suspected drug-drug interaction. Br J Clin Pharmacol 2019; 85(2): 454-6.
[http://dx.doi.org/10.1111/bcp.13810] [PMID: 30479035]
[78]
Varallo FR, Planeta CS, de Carvalho Mastroianni P. Effectiveness of pharmacovigilance: Multifaceted educational intervention related to the knowledge, skills and attitudes of multidisciplinary hospital staff. Clinics 2017; 72(1): 51-7.
[http://dx.doi.org/10.6061/clinics/2017(01)09] [PMID: 28226033]
[79]
Caldas ALL, Sá SPC, Oliveira Filho VC. Perceptions of pharmaceutical services among elderly people on polymedication. Rev Bras Enferm 2020; 73(5): e20190305.
[http://dx.doi.org/10.1590/0034-7167-2019-0305] [PMID: 32609218]
[80]
Anacleto TA, Perini E, Rosa MB, César CC. Medication errors and drug-dispensing systems in a hospital pharmacy. Clinics 2005; 60(4): 325-32.
[http://dx.doi.org/10.1590/S1807-59322005000400011] [PMID: 16138240]
[81]
Melo DO, Castro LL. Pharmacist’s contribution to the promotion of access and rational use of essential medicines in SUS. Cien Saude Colet 2017; 22(1): 235-44.
[http://dx.doi.org/10.1590/1413-81232017221.16202015] [PMID: 28076546]
[82]
Alibhai SMH, Jin R, Loucks A, et al. Beyond the black box of geriatric assessment: Understanding enhancements to care by the geriatric oncology clinic. J Geriatr Oncol 2018; 9(6): 679-82.
[http://dx.doi.org/10.1016/j.jgo.2018.03.012] [PMID: 29631899]
[83]
Suh Y, Ah YM, Lee E, Lee JY. Association of inappropriate polypharmacy with emergency department visits in older patients receiving anti-neoplastic therapy: A population-based study. Support Care Cancer 2021; 29(6): 3025-34.
[http://dx.doi.org/10.1007/s00520-020-05759-5] [PMID: 33037903]
[84]
Hernandez-Torres C, Korc-Grodzicki B, Hsu T. Models of clinical care delivery for geriatric oncology in Canada and the United States: A survey of geriatric oncology care providers. J Geriatr Oncol 2022; 13(4): 447-53.
[http://dx.doi.org/10.1016/j.jgo.2022.01.004] [PMID: 35101363]
[85]
Goede V, Stauder R. Multidisciplinary care in the hematology clinic: Implementation of geriatric oncology. J Geriatr Oncol 2019; 10(3): 497-503.
[http://dx.doi.org/10.1016/j.jgo.2018.09.003] [PMID: 30241779]
[86]
Giger AKW, Ditzel HM, Jørgensen TL, et al. Predictive value of geriatric oncology screening and geriatric assessment of older patients with cancer: A randomized clinical trial protocol (PROGNOSIS-RCT). J Geriatr Oncol 2022; 13(1): 116-23.
[http://dx.doi.org/10.1016/j.jgo.2021.07.005] [PMID: 34362713]
[87]
Xue D, Li P, Chen TH, Shi Q, Wang XS. Utility of a patient-reported symptom and functioning assessment tool for geriatric oncology care in China. Value Health Reg Issues 2022; 29: 28-35.
[http://dx.doi.org/10.1016/j.vhri.2021.08.001] [PMID: 34801883]
[88]
Kikuchi R, Broadwater G, Shelby R, et al. Detecting geriatric needs in older patients with breast cancer through use of a brief geriatric screening tool. J Geriatr Oncol 2019; 10(6): 968-72.
[http://dx.doi.org/10.1016/j.jgo.2019.04.010] [PMID: 31005647]
[89]
van Walree IC, Scheepers ERM, van den Bos F, van Huis-Tanja LH, Emmelot-Vonk MH, Hamaker ME. Clinical judgment versus geriatric assessment for frailty in older patients with cancer. J Geriatr Oncol 2020; 11(7): 1138-44.
[http://dx.doi.org/10.1016/j.jgo.2020.05.011] [PMID: 32576520]
[90]
McClennon J, Vonnes C, Dosal B, Reich RR, Mason TM, Extermann M. Integrating geriatric screening in the clinical setting: Recommendations for older adult oncology patients. J Geriatr Oncol 2021; 12(7): 1010-4.
[http://dx.doi.org/10.1016/j.jgo.2021.03.015] [PMID: 33814340]
[91]
Canouï-Poitrine F, Martinez-Tapia C, Paillaud E, et al. Geriatric impairments were directly and indirectly associated with mortality in older patients with cancer: A structural equation analysis. J Clin Epidemiol 2022; 148: 17-26.
[http://dx.doi.org/10.1016/j.jclinepi.2022.04.004] [PMID: 35398191]
[92]
Maas HAAM, Janssen-Heijnen MLG, Olde Rikkert MGM, Machteld Wymenga AN. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer 2007; 43(15): 2161-9.
[http://dx.doi.org/10.1016/j.ejca.2007.08.002] [PMID: 17855074]
[93]
Russo C, Terret C, Cropet C, Albrand G. Geriatric assessment in oncology: Moving the concept forward. The 20 years of experience of the Centre Léon Bérard geriatric oncology program. J Geriatr Oncol 2018; 9(6): 673-8.
[http://dx.doi.org/10.1016/j.jgo.2018.05.008] [PMID: 29866469]
[94]
Ishii R, Ogawa T, Ohkoshi A, Nakanome A, Takahashi M, Katori Y. Use of the Geriatric-8 screening tool to predict prognosis and complications in older adults with head and neck cancer: A prospective, observational study. J Geriatr Oncol 2021; 12(7): 1039-43.
[http://dx.doi.org/10.1016/j.jgo.2021.03.008] [PMID: 33757718]
[95]
Flood KL, Carroll MB, Le CV, Brown CJ. Polypharmacy in hospitalized older adult cancer patients: Experience from a prospective, observational study of an Oncology-Acute care for elders unit. Am J Geriatr Pharmacother 2009; 7(3): 151-8.
[http://dx.doi.org/10.1016/j.amjopharm.2009.05.002] [PMID: 19616183]
[96]
Deliens C, Deliens G, Filleul O, et al. Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist. J Geriatr Oncol 2016; 7(6): 463-70.
[http://dx.doi.org/10.1016/j.jgo.2016.05.001] [PMID: 27238734]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy